varicose veins


Varicose Veins Linked With Increased Risk of DVT

Mar 07, 2018

Varicose veins are significantly associated with risk of developing deep vein thrombosis (DVT), researchers reported in JAMA. | Read More


OPTALYSE PE Long Term Results Reinforce Safety and Efficacy of Shorter, Lower Dose EKOS® Therapy For Pulmonary Embolism

Feb 06, 2018

The authors followed the 12 month outcomes of 101 patients at 17 centers who participated in the OPTALYSE PE study in which the patients were randomized one of four cohorts. | Read More



Thrombectomy Effective Up to 16 Hours: DEFUSE 3 Trial

Jan 31, 2018

Current recommendations say that patients are eligible for thrombectomy within 6 hours of a stroke, but newly released results from the DEFUSE 3 trial suggest that the window of opportunity may extend up to 16 hours in certain patients. | Read More



Early TEVAR May Be Appropriate in Some Patients

Jan 19, 2018

Using certain clinical and anatomic features as a guide, it may be possible to predict whether patients with medically managed type B aortic dissection (TBAD) will benefit from early TEVAR. | Read More



FDA Approves Catheter for Use in PAD

Jan 10, 2018

The catheter is indicated for treatment of peripheral arterial disease (PAD), and it is designed to aid in true lumen passage of lesions, both above and below the knee, in the peripheral vasculature. | Read More

eluvia stent


MAJESTIC Trial Evaluates Long-Term Treatment Durability for Eluvia Stent

Dec 02, 2017

Building on the initial results of the MAJESTIC trial, researchers examined treatment durability at the 3-year mark. | Read More



Radiation During EVAR Damages Operators’ DNA

Nov 20, 2017

A study published in Circulation has shown for the first time that an acute DNA damage response occurs in operators performing fluoroscopically-guided interventions such as endovascular aortic repair (EVAR). | Read More


FDA Approves New Rivaroxaban Dosing for Extended VTE

Nov 01, 2017

The 10 mg once-daily dose of rivaroxaban (Xarelto) has been approved by the FDA for reducing continued risk for recurrent venous thromboembolism (VTE) after patients complete at least 6 months of initial anticoagulation therapy. | Read More

blood clot


Prospective, Multicenter Trials Assesses Safety of Convertible IVC Filter

Oct 12, 2017

The safety and conversion rate of the VenaTech Convertible filter were evaluated in a prospective, multicenter trial. | Read More

arterial disease


Novel Paclitaxel-Matrix-Coated Balloon Catheter Outperforms Uncoated Balloon Angioplasty

Oct 12, 2017

Researchers compared treatment with paclitaxel–resveratrol-matrix-coated peripheral balloon angioplasty versus plain old balloon angioplasty in patients with symptomatic peripheral artery occlusive disease in femoro-popliteal lesions. | Read More